Core Viewpoint - The announcement highlights a strategic collaboration between Baiaosaitu-B (02315) and Yushibo Co., Ltd. to accelerate the development of bispecific antibody-drug conjugates (BsAD2C) through a structured evaluation mechanism [1] Group 1: Agreement Details - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaosaitu [1] - Baiaosaitu will receive an upfront payment for the option, and upon exercise of the option by Yushibo, Baiaosaitu will also receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and future product sales royalties [1] Group 2: Collaboration Background - This agreement deepens the collaboration initiated earlier in the year, which focused on evaluating and screening promising bispecific antibodies and dual-load antibody-drug conjugate (ADC) candidates [1] - The combination of Baiaosaitu's RenLite® fully human light chain antibody development platform with Yushibo's antibody-drug conjugate (AD2C) technology is seen as a promising technical pathway for the development of a new generation of BsAD2C [1] Group 3: Project Advancement - The expanded collaboration aims to leverage the complementary strengths of both platforms to advance the design of next-generation ADC molecules, addressing limitations observed in traditional ADC projects [2] - The collaboration team is steadily progressing through key evaluation milestones, with decisions based on ongoing research data and Yushibo's internal processes and option exercise criteria [2]

Group 1 - The core viewpoint of the article highlights that Baiaosaitu-B (02315) experienced a significant stock price increase, reaching a new high of 39.46 HKD, with a current increase of 7.86% at 38.72 HKD and a trading volume of 17.64 million HKD [1] - On January 9, Baiaosaitu announced a licensing agreement with Yushibo to systematically evaluate the BsADC projects, aiming to accelerate the development of BsAD2C [1] - The agreement grants Yushibo an option for exclusive global licensing of two BsADC projects from Baiaosaitu, which will receive an upfront payment and subsequent payments upon the exercise of the option, including milestone payments and revenue sharing [1] Group 2 - According to recent research from Cinda Securities, Baiaosaitu's business model, which includes sales of model animals and preclinical pharmacological evaluations, is experiencing rapid growth [1] - Compared to peers, Baiaosaitu's business model is unique, focusing on high-margin humanized mouse strains and avoiding low-margin standard strains, leading to high utilization of cage resources and international expansion capabilities [1]